

## Grifols and Hologic embark on a unique collaboration for COVID-19 testing in Spain

The deal will allow significantly higher volume of molecular diagnostic tests across the country

**Barcelona, Spain, and Marlborough, Mass., June 10, 2020** - Hologic, Inc, a global medical technology company with a speciality in molecular diagnostics for infectious diseases, and Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that they will combine forces in Spain to substantially increase the country's testing capacity for COVID-19 to help meet its high testing needs to help fight the COVID-19 pandemic. This is especially relevant as the country is gradually de-escalating and tourism will soon return which will significantly help re-open the economy safely.

As part of this unique collaboration, Hologic has agreed that Grifols will be able to extend sales of its Procleix® SARS CoV-2 assay into molecular diagnostic testing laboratories in Spain. This ensures that all regions within the country will be able to access a SARS-CoV-2 assay.

“As the global demand for testing continues to increase, this collaboration agreement will make the test available to a wider range of laboratories across the country, significantly increasing the capacity of COVID-19 testing in Spain,” said Jose Yebra, General Manager Italy, Spain & Portugal at Hologic. “Our combined efforts will enable a faster, more widespread adoption of high volume, high throughput testing.”

The Procleix® SARS-CoV-2 assay, developed by Grifols, runs on the Procleix® Panther® system, an automated, high-throughput molecular diagnostic platform. Both Procleix® and Panther® systems use the same proprietary technology called TMA (Transcription Mediated Amplification), owned by Hologic and exclusively licensed to Grifols for use in donor screening.

This process makes multiple copies of unique genetic sequences that are specific to a virus, in this case SARS-CoV-2, facilitating its rapid and accurate detection. The Procleix® Panther® system can provide initial results in approximately three and a half hours and process more than 1,000 coronavirus tests in a 24-hour period.

“Testing for the presence of the virus continues to play a significant role in Spain's continuous fight against COVID-19,” said Gregorio Alcantarilla, Director Division Diagnostic Iberia at Grifols. “Our collaboration with Hologic will enable us to support a wider range of laboratories across the country in meeting the demand for these tests over the coming weeks and months.”

**About COVID-19**

For more information about the novel coronavirus, visit:  
<https://www.msrebs.gob.es/en/organizacion/portada/home.htm>

**About Procleix® Panther®**

The Procleix® Panther® system is an automated molecular biology analyzer for high performance clinical diagnostics capable of processing more than 1,000 samples daily per unit.

**About Panther®**

The Panther molecular diagnostics system is a fully automated, sample-to-result platform that can be used in low-, medium- or high-throughput laboratories. With a small footprint, adaptable workflow options and consolidated testing menu, it combines women's health, sexually transmitted infections and viral testing, which can all be done simultaneously.

**About Aptima® SARS-CoV-2 assay**

The Aptima SARS-CoV-2 assay has been clinically validated and CE-marked. It runs on Hologic's fully automated Panther system.

**About Grifols**

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2019, Grifols' economic impact in its core countries of operation was 8.5 billion euros. The company also generated 148,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [www.grifols.com](http://www.grifols.com)

**About Hologic**

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit [www.hologic.com](http://www.hologic.com).

## Media Contacts:

### Grifols

#### España

Raquel Lumbreras

[Raquel\\_lumbreras@duomocomunicacion.com](mailto:Raquel_lumbreras@duomocomunicacion.com)

Borja Gómez

[Borja\\_gomez@duomocomunicacion.com](mailto:Borja_gomez@duomocomunicacion.com)

Duomo Comunicación – **Gabinete de prensa de Grifols**

**Tel. +34 659 57 21 85 / +34 650 40 22 25**

#### International

Brad Pick

**Grifols Corporate Communications**

[Brad.pick@grifols.com](mailto:Brad.pick@grifols.com)

**Tel. +34 93 571 00 02**

### Hologic

#### Spain

Laura Mayoral García

[lauramayoral@cicerocomunicacion.es](mailto:lauramayoral@cicerocomunicacion.es)

Esteban Bravo

[ebravo@cicerocomunicacion.es](mailto:ebravo@cicerocomunicacion.es)

Cícero Comunicación

**Tel. +34 91 750 06 40 / +34 685 99 21 98**

#### International

José Yebra

General Manager Italy, Spain & Portugal

Hologic

[Jose.yebra@hologic.com](mailto:Jose.yebra@hologic.com)

**Tel. +34 62 863 96 73**

### **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.